Zum Seiteninhalt springen

Aims of call:

The funding is intended as seed financing to reach phase I/IIa clinical trials for Advanced Therapies and boost the translational chain, serving as basis to apply for substantial third-party funds. Projects should have a clear clinical or technical translational pathway and be innovative in nature. Projects must also be interdisciplinary, including a minimum of 2 BIH PIs from different fields or disciplines and a Charité clinical partner (unless covered by a BIH PI).

Examples of what may be funded include, but are not limited to:

  1. Studies to compare methods (e.g. manufacturing methods, different devices) in order to find the most suitable method for the project
  2. Development/implementation of potency assays
  3. Development/implementation of assays related to characterization of the product
  4. Development/implementation of assays related to stability/impurity
  5. Consultation with regulatory experts to assess all the above (especially points 2,3,4)

Proof of concept or repeat studies will not be considered for funding in this call.

Expected outcomes:

  • Expected that the work provides the basis for application for substantial third party funding (DFG, BMBF, EU) for phase I/IIA clinical trials or first-in-man studies.
  • Project makes a clear advance in the translational pipeline as evidenced by progression to clinical trial phase I/IIa or first-in-man study readiness.


  • Applications from minimum of 2 BIH PIs from different fields or disciplines in cooperation with a Charité clinical partner (unless covered by a BIH PI) will be eligible for funding.
  • Only one lead application per PI.

Funding details:

  • Funding up to €150,000/year can be provided.
  • Max. 2 years funding (If 2 years funding is applied for, progress evaluation will take place after year 1 of funding)
  • Funding can be used to cover all costs (as long as duly justified) except travel.

How to apply:

  • Applications must be written in English and received by 23:59 h on 29th August 2021. Applications received after this deadline will not be considered.
  • Applications must follow the template provided.
  • Completed applications should be sent to: contact@b-crt.de

Evaluation criteria and review process:

Applications will be evaluated by the extended BCRT steering committee in cooperation with Charité-BIH Innovation based on the criteria outlined in the application template. These criteria are in accordance with the development of ToMAP (Translation Oriented Means-Model of Assessing Projects).

In brief applications will be evaluated on:

  • novelty and state-of-the-art
  • IP protection and exploitation strategy
  • translational character of the project and commercial outlook
  • cross disciplinarity
  • feasibility of project success (contingency plans should be in place)
  • suitability for future 3rd party funding (3rd party funding should already be considered when planning the initial proposal)

All applicants will be invited to present their proposals as a pitch to the BCRT steering committee starting from calendar week 37: week beginning 13th September 2021.

Results will be announced during calendar week 38: Week beginning 20th September 2021, with the expectation that funding commences in January 2022.